UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2026
Commission file number: 001-41557
CLEARMIND
MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
Attached hereto and incorporated
herein is the Registrant’s press release issued on November 19, 2026, titled “Clearmind Medicine Expands PTSD Patent Portfolio
with Hong Kong Patent Application Publication.”
The first four paragraphs
of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration
Statements on Form F-3 (File Nos. 333-275991,
333-270859, 333-273293,
333-290404, 333-293521
and 333-295455) and Form S-8
(File No. 333-283695), filed
with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Clearmind Medicine, Inc. |
| |
(Registrant) |
| |
|
|
| Date: November 19, 2026 |
By: |
/s/ Adi Zuloff-Shani |
| |
Name: |
Adi Zuloff-Shani |
| |
Title: |
Chief Executive Officer |
3
Exhibit 99.1
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong
Patent Application Publication
Vancouver, Canada, Nov. 19, 2026 (GLOBE
NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage
biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of
neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the
publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic
Stress Disorder (“PTSD”) and other mental health disorders.
The patent application is part of the Company’s exclusive worldwide
licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The compounds
were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind
holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.
The Hong Kong patent publication expands Clearmind’s global patent
application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application
supports the Company’s strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.
According to market
research by Heimdall Insights, the global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to
reach $24.8 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 5.5%. In addition, GlobalData projects
that the PTSD pharmaceutical market across seven major markets is projected to grow from $1.2 billion in 2024 to $5.5 billion
by 2034, at a CAGR of 16.1%, reflecting anticipated demand for innovative treatment options.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech
company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve
widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual property portfolio currently consists
of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted
and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol
“CMND.”
For further information, visit: https://www.clearmindmedicine.com or
contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements
when it discusses the potential of the novel compounds covered by the patent application; the Company’s ability to develop, manufacture,
and commercialize such compounds; the potential commercial opportunities associated with such compounds; the Company’s strategy to seek
intellectual property protection for its novel therapeutic candidates across key global markets; and expected growth in the PTSD pharmaceutical
market. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will
issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s
current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is
made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including,
but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and
subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates
with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,
and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible
for the contents of third-party websites.